Metabolicheskie i organoprotektivnye effekty kombinatsii amlodipina i atorvastatina u bol'nykh s metabolicheskim sindromom


如何引用文章

全文:

详细

参考

  1. Чазова И.Е., Мычка В.Б. Метаболический синдром. М.: Медиа Медика, 2008.
  2. Жернакова Ю.В., Чазова И.Е., Мычка В.Б., Олимпиева С.П. Тяжесть метаболического синдрома определяется числом его компонентов. Системные гипертензии. 2011; 1.
  3. Kloner RA, Sowers JR, DiBona GF et al. Sex and agerelated antihypertensive effects of amlodipine. Am J Cardiol 1996; 77: 713-22.
  4. Kario K, Pickering TG, Umeda Y et al. Morning surge in blood pressure as a predictor of silent and clinical cerebrovascular disease in elderly hypertensives: a prospective study. Circulation 2003; 107: 1401-06.
  5. Kario K, Shimada K, Pickering TG. Clinical implication of morning blood pressure surge in hypertension. J Cardiovasc Pharmacol 2003; 42 (Suppl. 1): S87-91.
  6. Julius S, Kjeldsen SE, Weber M et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipin: the VALUE randomized trial. Lancet 2004; 363 (9426): 2022-3.
  7. Liebson PR, Grandits G, Dianzumba. Comparison of five antihypertensive monotherapies and placebo for change in left ventricular mass in patients receiving nutritional-hygienic therapy in thе Treatment of Mild Hypertension Study (TOMHS). Circulation 1995; 91: 698-706.
  8. Long-term effects of amlodipine and lisinopril on left ventricular mass and diastolic function in elderly previously untreated hypertensive patients: the ELVERA trial. J Hypertens 2001; 19 (2): 303-9.
  9. Tatti P, Pahor M, Byington R et al. Outcome results of the fosinopril versus amlodipine cardiovascular events trial (FACET) in patients with hypertension and N1DDM. Diabetes Care 1998; 21: 597-603.
  10. The ALLHAT Officers and Coordinators. Major outcomes in high-risk hypertensive patients randomized to ACE inhibitor or calcium channel blocker vs diuretic (ALLHAT). JAMA 2002; 288: 2981-97.
  11. Dahlof B, Sever P, Poulter N et al. The enhanced prevention of cardiovascular events with amlodipine-based regimen compared with an atenolol-based regimen. The Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomized controlled trial. Lancet 2005; 366: 895-906.
  12. Ahaneku JE, Taylor GO, Agbedana EO et al. Effects of amlodipine on plasma lipid and lipoprotein levels in hypertensive parients. J Intern Med 1992; 232: 489-93.
  13. Sever PS, Dahlof B, Poulter NR, Wedel H et al. ASCOT investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial - Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003; 361: 1149-58.
  14. Collhoun HM, Betteridge DJ, Durrington PN et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004; 364 (9435): 685-96.
  15. Balantyne C et al. Lipids and CVD management: towards a global consensus. Eur Heart J 2005; 26: 2224-31.
  16. Strazzullo P et al. Do statins reduce blood pressure? A meta-analysis of randomized, controlled trials. Hypertension 2007; 49: 792-8.
  17. Рекомендации экспертов ВНОК по диагностике и лечению МС (2-й пересмотр). Кардиоваск. тер. и профилакт. 2009; 7 (6, Прил. 2).
  18. Рекомендации экспертов ВНОК по диагностике и лечению артериальной гипертензии (4-й пересмотр). Системные гипертензии. 2010; 3: 5-26.
  19. Matthews DR, Hosker JP, Rudenski AS et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-9.
  20. Nagueh SF, Middleton KJ, Kopelen HA et al. Doppler tissue imaging: a noninvasive technique for evaluation of left ventricular relaxation and estimation of filling pressures. J Am Coll Cardiol 1997; 30 (6): 1527-33.
  21. Appleton CA, Hatle LK, Popp RL. Relation of transmitral flow velocity patterns to left ventricular diastolic function: New insights from a combined hemodynamic and Doppler echocardiographic study. J Am Coll Cardiol 1988; 12: 426-40.
  22. Рекомендации экспертов ВНОК по диагностике и коррекции нарушений липидного обмена с целью профилактики и лечения атеросклероза. Кардиоваск. тер. и профилакт. 2007; 6 (6, Прил. 3).
  23. Jorgensen B, Simonsen S, Endresen K et al. Restenosis and clinical outcome in patients treated with amlodipine after angioplasty: results from the Coronary AngioPlasty Amlodipine REStenosis Study (CAPARES). J Am Coll Cardiol 2002; 35: 592-99.
  24. Nissen SE, Tuzcu EM, Libby P et al. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. JAMA 2004; 292: 2217-26.
  25. Sasaki J, Iwashita M, Kono S et al. Statins: beneficial or adverse for glucose metabolism J Atheroscler Thromb 2006; 13: 123-9.

补充文件

附件文件
动作
1. JATS XML
下载


Creative Commons License
此作品已接受知识共享署名-非商业性使用-相同方式共享 4.0国际许可协议的许可。
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ЭЛ № ФС 77 - 83918 от 12.09.2022 г. 
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 83917 от 12.09.2022 г.


##common.cookie##